Adlai Nortye (ANL)

• Market cap: $278M
• 1 day: -5.16%
• 5 days: -14.03%
• 1 month: -21.62%
• 3 months: 359.76%
• 6 months: 321.23%
• Year to date: 446.38%
• 1 year: 235.11%
• 5 years: -49.73%
• 10 years: -49.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Employees: 123